Insulet (PODD) reported $2.7B in revenue for fiscal 2025, +30.7% year on year. That ranks #1176 by revenue among 2853 SEC filers and #105 in Healthcare. Net income was $247M, a net margin of 9.1%. Revenue has grown 25.1% a year on average since 2014 ($231M then). The fiscal 2025 balance sheet shows $3.2B in total assets, $716M in cash and $931M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $2.7B | +30.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $1.9B | +34.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $474M | +53.4% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $247M | −40.9% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $569M | +32.3% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $192M | +53.4% | FY20252025-12-31 |
| Total assetsAssets | $3.2B | +3.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.5B | +25.1% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $716M | −24.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtAndCapitalLeaseObligations | $931M | −28.2% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $762M | $91.1M | Open → |
| Q2 20262026-06-30 | $802M | $95.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 59 of 161 companies compared | 9.1% | |
| Operating marginRank 46 of 160 companies compared | 17.5% | |
| R&D as share of revenueRank 42 of 102 companies compared | 11.1% | |
| Cash as share of revenueRank 31 of 160 companies compared | 26.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Insulet Corp
- Ticker
- PODD
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001145197
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 18, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| QuidelorthoQDEL | $2.7B | −$1.1B |
| Fortrea HoldingsFTRE | $2.7B | −$989M |
| Envista HoldingsNVST | $2.7B | $47.0M |
| InsuletPODD | $2.7B | $247M |
| Medpace HoldingsMEDP | $2.5B | $451M |
| ChemedCHE | $2.5B | $265,238 |
| Teladoc HealthTDOC | $2.5B | −$200M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Insulet — Key figures |url=https://companiesranked.com/en/company/insulet |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Insulet — Key figures. CompaniesRanked. https://companiesranked.com/en/company/insuletBibTeX
@misc{companiesranked-en-company-insulet-2026,
author = {{CompaniesRanked}},
title = {{Insulet — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/insulet}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001145197-26-000028 · February 18, 2026
{{cite web |title=Insulet — Key figures — 10-K (0001145197-26-000028) |url=https://www.sec.gov/Archives/edgar/data/1145197/000114519726000028/podd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-18}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.